A Look At The Next Gen Obesity Pipeline Coming Out Of China

GIP/GLP-1R Ahead, Amylin/Activin At Early Stage

 
• By Xu Hu
  
What does the next phase of China-originated anti-obesity therapies hold? (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from China

More from Focus On Asia